Eisai, Biogen get FDA approval of Alzheimer's drug, apply for full approval

Eisai, Biogen get FDA approval of Alzheimer’s drug, apply for full approval

(Reuters) – The U.S. Food and Drug Administration on Friday approved the Alzheimer’s drug licanimab, which was developed by Eisai Ltd. (4523.T) and Biogen Inc. (BIIB.O) for patients in the early stages of the mental-wasting disease. On Saturday, Eisai and Biogen said the Japanese drugmaker had applied for full FDA approval of the drug. The …

Eisai, Biogen get FDA approval of Alzheimer’s drug, apply for full approval Read More »